PMID- 35116874
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 8
IP  - 4
DP  - 2019 Aug
TI  - IL-35 inhibits CD8(+) T cells activity by suppressing expression of costimulatory 
      molecule CD28 and Th1 cytokine production.
PG  - 1319-1325
LID - 10.21037/tcr.2019.07.30 [doi]
AB  - BACKGROUND: Interleukin-35 (IL-35), a novel immune-suppressing cytokine, can 
      promote tumor angiogenesis and inhibits anti-tumor cytotoxic lymphocyte response. 
      Here, we aimed to investigate the potential mechanism of the effects of IL-35 on 
      anti-tumor cytotoxic lymphocyte. METHODS: Dendritic cells (DCs) were used to 
      induce anti-tumor cytotoxic lymphocyte. Flow cytometry, carboxyfluorescein 
      succinimidyl ester staining, ELISA assay and western blotting were used to 
      analyze the effect of IL-35 on anti-tumor cytotoxic lymphocyte. RESULTS: We 
      observed that IL-35 inhibited the expression of costimulatory molecule CD28 on 
      CD8(+) T cell surface and Th1 cytokine production. However, IL-35 did not inhibit 
      anti-tumor cytotoxic lymphocyte proliferation nor enhance the expression of 
      apoptosis-related proteins of anti-tumor cytotoxic lymphocyte. Moreover, IL-35 
      did not repress the expression of Fas ligand (FasL) on cytotoxic lymphocyte 
      surface. CONCLUSIONS: Our findings revealed that IL-35 can inhibit CD8(+) T cells 
      activity by suppressing the expression of costimulatory molecule CD28 and Th1 
      cytokine production.
CI  - 2019 Translational Cancer Research. All rights reserved.
FAU - Jiang, Hua
AU  - Jiang H
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Department of Radiation Oncology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Eye Center, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, 
      Hangzhou 310009, China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Department of Radiation Oncology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Eye Center, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, 
      Hangzhou 310009, China.
FAU - Yan, Mao-Xiao
AU  - Yan MX
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Department of Radiation Oncology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Eye Center, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, 
      Hangzhou 310009, China.
FAU - Wu, Wei
AU  - Wu W
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Department of Radiation Oncology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310009, China.
AD  - Eye Center, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, 
      Hangzhou 310009, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8797787
OTO - NOTNLM
OT  - Costimulatory molecule
OT  - cytokine
OT  - cytotoxic lymphocyte
OT  - interleukin-35 (IL-35)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr.2019.07.30). The authors have 
      no conflicts of interest to declare.
EDAT- 2019/08/01 00:00
MHDA- 2019/08/01 00:01
PMCR- 2019/08/01
CRDT- 2022/02/04 05:49
PHST- 2019/03/02 00:00 [received]
PHST- 2019/05/31 00:00 [accepted]
PHST- 2022/02/04 05:49 [entrez]
PHST- 2019/08/01 00:00 [pubmed]
PHST- 2019/08/01 00:01 [medline]
PHST- 2019/08/01 00:00 [pmc-release]
AID - tcr-08-04-1319 [pii]
AID - 10.21037/tcr.2019.07.30 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2019 Aug;8(4):1319-1325. doi: 10.21037/tcr.2019.07.30.